Biologics APIs

Jan 12, 2018
By Pharmaceutical Technology Editors
The acquisition, valued at EUR 520 million (US$631 million), would expand Takeda’s late-stage pipeline in gastroenterology and would extend an already existing collaboration between the two companies.
Jan 08, 2018
Graham Reynolds, vice-president and general manager, Global Biologics at West Pharmaceutical Services, Inc., shares insights on key considerations when developing a biologic drug product in a prefilled syringe.
Jan 05, 2018
By Pharmaceutical Technology Editors
The companies aim to discover and develop locked nucleic acid oligonucleotides as orally available therapies for treating inflammatory bowel diseases.
Jan 05, 2018
By Pharmaceutical Technology Editors
The companies aim to develop a potential zinc finger protein transcription factor-based gene therapy for treating Lou Gehrig’s disease.
Jan 02, 2018
Pharmaceutical Technology
The development of new packaging solutions that are fit for drugs of the future requires close collaboration between the pharmaceutical manufacturer and its packaging suppliers and machine vendors.
Dec 20, 2017
By Pharmaceutical Technology Editors
FDA has approved a new gene therapy for treating patients born with a rare, inherited vision loss.
Dec 19, 2017
By Pharmaceutical Technology Editors
The company has completed development of a first-generation production process for its chimeric antigen receptor regulatory T cell product portfolio and is selecting a CMO for clinical supply.
Dec 19, 2017
By Pharmaceutical Technology Editors
Sanofi Genzyme and its partner, Alnylam Pharmaceuticals, have filed a marketing authorization application with EMA for an investigational RNAi therapeutic for treating a genetic-based disease.
Dec 18, 2017
By Pharmaceutical Technology Editors
The US Court of Appeals for the Federal Circuit has decided in favor of Novartis’ Sandoz in rendering the opinion that Amgen cannot use state laws to prohibit or delay the marketing of biosimilars.
Dec 14, 2017
By Pharmaceutical Technology Editors
Abzena has entered into a Master Services Agreement with a US biotech company to provide process development and manufacturing services to progress a novel antibody-drug conjugate (ADC) to clinical trials.
native1_300x100
lorem ipsum